Influence of eotaxin 67G>A polymorphism on plasma eotaxin concentrations in myocardial infarction survivors and healthy controls

Atherosclerosis

Volumn 189, Issue 2, 2006, Pages 458-463

  Sheikine, Yuri ^a   Olsen, Birgitta ^b   Gharizadeh, Baback ^c   Jatta, Ken ^b   Tornvall, Per ^a   Ghaderi, Mehran ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokines; Coronary artery disease; Eotaxin (CCL11); Genotype; Myocardial infarction; Plasma levels; Pyrosequencing; Single nucleotide polymorphism

Indexed keywords

EOTAXIN;

ADULT; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TISSUE LEVEL;

CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; DNA; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWEDEN;

EID: 33750347649     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.01.003     Document Type: Article

References (14)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
2. Sheikine Y., and Hansson G.K. Chemokines as potential therapeutic targets in atherosclerosis. Curr Drug Targets 7 (2006) 13-28
3. Haley K.J., Lilly C.M., Yang J.H., et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 102 (2000) 2185-2189
4. Kodali R.B., Kim W.J., Galaria I.I., et al. CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol 24 (2004) 1211-1216
5. Economou E., Tousoulis D., Katinioti A., et al. Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int J Cardiol 80 (2001) 55-60
6. Mosedale D.E., Smith D.J., Aitken S., et al. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis 183 (2005) 268-274
7. Miyamasu M., Sekiya T., Ohta K., et al. Variations in the human CC chemokine eotaxin gene. Genes Immun 2 (2001) 461-463
8. Nakamura H., Luster A.D., Nakamura T., et al. Variant eotaxin: its effects on the asthma phenotype. J Allergy Clin Immunol 108 (2001) 946-953
9. Chang H.S., Kim J.S., Lee J.H., et al. A single nucleotide polymorphism on the promoter of eotaxin1 associates with its mRNA expression and asthma phenotypes. J Immunol 174 (2005) 1525-1531
10. Zee R.Y., Cook N.R., Cheng S., et al. Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis 175 (2004) 91-94
11. Lundberg G.A., Kellin A., Samnegård A., et al. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. J Intern Med 257 (2005) 415-422
12. Samnegård A., Silveira A., Lundman P., et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 258 (2005) 411-419
13. Eriksson P., Deguchi H., Samnegård A., et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 24 (2004) 551-557
14. Fakhrai-Rad H., Pourmand N., and Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat 19 (2002) 479-485